I. van Zanten-Przybysz

Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.

I. van Zanten-Przybysz, Carla F.M. Molthoff, Jan C. Roos et al. · PubMed · 2000 · 49 citations

Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v.vs. i.p.

I. van Zanten-Przybysz, Carla F.M. Molthoff, Jan C. Roos et al. · International Journal of Cancer · 2001 · 40 citations

Engineering, Oncologic Imaging, Immunology +18

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

I. van Zanten-Przybysz, Carla F.M. Molthoff, J W T Klein Gebbinck et al. · Journal of Cancer Research and Clinical Oncology · 2002 · 36 citations · Full text

Multiple Injections, Medicine, Immunology +9

Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls

F.G.M. Snijdewint, Silvia von Mensdorff‐Pouilly, Augustine H. Karuntu-Wanamarta et al. · Cancer Immunology Immunotherapy · 1999 · 34 citations · Full text

Cancer Immunosurveillance, Muc1 Mucin, Endocrine-related Cancer +12

Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: I.v. vs. i.p.

I. van Zanten-Przybysz, Carla F.M. Molthoff, Jan C. Roos et al. · International Journal of Cancer · 2001 · 13 citations

Drug Targeting, Medicine, Immunology +8